Pakistan\u2019s pharmaceutical sector has quietly morphed into a compelling value play. Despite major regulatory relief, margin expansion, and earnings growth, valuations across the board remain depressed\u2014presenting an attractive entry point for long-term investors.<\/p>\n\n\n\n
Pharma companies listed on the PSX have historically traded at a forward P\/E multiple of around 20x<\/strong>. Currently, leading players such as AGP<\/a><\/strong>, ABOT<\/a><\/strong>, GLAXO<\/a><\/strong>, and HALEON <\/a><\/strong>are trading at forward CY25E P\/E multiples between 12x and 15x<\/strong>, well below their historical average and global comparables.<\/p>\n\n\n\n <\/p>\n\n\n\n The disconnect between price and value seems largely psychological\u2014a carryover from past volatility. But recent developments have altered the sector’s risk profile dramatically:<\/p>\n\n\n\n With margins improving and top-line growth accelerating, a valuation rerating looks inevitable\u2014especially for players with strong brand portfolios and high non-essential product mix like AGP and ABOT.<\/p>\n\n\n\n Additionally, strong dividend yields<\/strong> (3\u20134% range) make the current holding period rewarding, even before capital appreciation.<\/p>\n\n\n\n If you\u2019ve been waiting for a window to enter Pakistan\u2019s pharmaceutical sector, this might be it. With valuations at a steep discount and structural improvements underway, investors could benefit from both earnings growth<\/strong> and multiple expansion<\/strong>.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" Pakistan\u2019s pharmaceutical sector has quietly morphed into a compelling value play. Despite major regulatory relief, margin expansion, and earnings growth, valuations across the board remain depressed\u2014presenting an attractive entry point for long-term investors.<\/p>\n","protected":false},"author":9252,"featured_media":6581,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[154,343],"tags":[380,200,198,95,159],"class_list":["post-9422","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","category-sector-analysis","tag-abot","tag-agp","tag-glaxo","tag-haleon","tag-pharma"],"featured_image_src":{"landsacpe":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/pharma-sector-psx-2-1140x445.jpg",1140,445,true],"list":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/pharma-sector-psx-2-463x348.jpg",463,348,true],"medium":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/pharma-sector-psx-2-300x188.jpg",300,188,true],"full":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/pharma-sector-psx-2.jpg",1920,1200,false]},"_links":{"self":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/9422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/users\/9252"}],"replies":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/comments?post=9422"}],"version-history":[{"count":2,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/9422\/revisions"}],"predecessor-version":[{"id":9466,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/9422\/revisions\/9466"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/media\/6581"}],"wp:attachment":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/media?parent=9422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/categories?post=9422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/tags?post=9422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Company<\/th> CY25E EPS<\/th> CY25E P\/E<\/th> Fair Value (PKR\/sh)<\/th> Current Price (PKR\/sh)<\/th> Upside<\/th><\/tr><\/thead> AGP<\/td> 13.0<\/td> 14.3x<\/td> 257<\/td> 185<\/td> 39%<\/td><\/tr> ABOT<\/td> 81.0<\/td> 11.9x<\/td> 1,307<\/td> 961<\/td> 36%<\/td><\/tr> GLAXO<\/td> 31.5<\/td> 12.4x<\/td> 503<\/td> 390<\/td> 29%<\/td><\/tr> HALEON<\/td> 49.0<\/td> 15.2x<\/td> 878<\/td> 744<\/td> 18%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n What\u2019s driving the discount?<\/h2>\n\n\n\n
\n
A rerating in the making?<\/h2>\n\n\n\n
Investor takeaway<\/h2>\n\n\n\n